The Role of Biobanks in Oncology Research – A Portuguese Perspective


  • Mónica Gomes Portuguese Institute of Oncology
  • Ana Luísa Teixeira University of Porto
  • Ana Coelho Faculty of Medicine of University of Porto
  • Rui Medeiros Faculty of Health Sciences of Fernando Pessoa University
  • António Araújo Medical Oncology Service of Centro Hospitalar do Porto



Biobank, cancer research, cancer biomarkers


Approximately, 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Cancer is a group of diseases characterized by uncontrolled growth, spread of abnormal cells and is a leading cause of death in both more and less economically developed countries. The growth in our knowledge of cancer biology has led to remarkable progress in cancer prevention, early detection and treatment. Recent years have seen a remarkable progress in the basic, translational and clinical research in cancers. During carcinogenesis several genetic and epigenetic alterations occur and a molecular approach based on the detection of these molecular alterations can permit the definition of molecular signatures specific for different tumors, allowing the definition of molecular biomarkers. These markers can be found in a variety of fluids, tissues and cell lines, and can be used for screening the general population, for differential diagnosis in symptomatic patients and for clinical staging of cancer. Furthermore, the biomarkers can be used to evaluate response to treatment, to assess disease recurrence through monitoring and as prognostic indicators of disease progression. The advances in the molecular knowledge and technology from research is based on the study of different types of biological samples, being necessary the collection, processing, preservation, stored and maintenance of these samples required an ordered and structured plan with the consequent creation of a biobank. The promotion and operation of biobanks provide to scientists the opportunity to access to quality samples and associated data, representing an essential milestone in shortening the time between research and clinical application, improving the effectiveness of research.


[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians 2015; 65(2): 87-108.

[2] Popper HH, Ryska A, Timar J, Olszewski W. Molecular testing in lung cancer in the era of precision medicine. Translational lung cancer research 2014; 3(5): 291-300.
[3] Nalejska E, Maczynska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Molecular diagnosis & therapy 2014; 18(3): 273-84.
[4] Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism 2015; 64(3 Suppl 1): S16-21.
[5] Henry NL, Hayes DF. Cancer biomarkers. Molecular oncology 2012; 6(2): 140-6.
[6] Sethi S, Ali S, Philip PA, Sarkar FH. Clinical advances in molecular biomarkers for cancer diagnosis and therapy. International journal of molecular sciences 2013; 14(7): 14771-84.
[7] La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature reviews Clinical oncology 2011; 8(10): 587-96.
[8] Shariat SF, Scherr DS, Gupta A, Bianco FJ, Jr., Karakiewicz PI, Zeltser IS, et al. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol 2011; 64(8): 681-94.
[9] Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nature clinical practice Oncology 2008; 5(10): 588-99.
[10] Aggarwal C. Targeted therapy for lung cancer: present and future. Annals of palliative medicine 2014; 3(3): 229-35.
[11] Song G, Liu Y, Wang Y, Ren G, Guo S, Ren J, et al. Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib. Clin Chim Acta 2015; 440: 44-8.
[12] Vadakara J, Borghaei H. Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmacogenomics and personalized medicine 2012; 5: 113-23.
[13] Korpanty GJ, Graham DM, Vincent MD, Leighl NB. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in oncology 2014; 4: 204.
[14] Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153): 561-6.
[15] Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368(25): 2385-94.
[16] Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371(23): 2167-77.
[17] Purriños NDGNC. Biobancos y su importancia en el ámbito clínico y científico en relación con la investigación biomédica en Espanã. Reumatol Clin 2014; 10: 304-8.
[18] Budimir D, Polasek O, Marusic A, Kolcic I, Zemunik T, Boraska V, et al. Ethical aspects of human biobanks: a systematic review. Croatian medical journal 2011; 52(3): 262-79.
[19] Hoeyer K. The ethics of research biobanking: a critical review of the literature. Biotechnology & genetic engineering reviews 2008; 25: 429-52.
[20] Riegman PH, de Jong BW, Llombart-Bosch A. The Organization of European Cancer Institute Pathobiology Working Group and its support of European biobanking infrastructures for translational cancer research. Cancer Epidemiol Biomarkers Prev 2010; 19(4): 923-6.
[21] OECD. Guidelines on human biobanks and genetic research databases 2009.
[22] Reis ST, Feitosa EB, Pontes-Junior J, Marin CC, Abe DK, Crippa A, et al. Tumor banks: the cornerstone of basic research in urology. International braz j urol : official journal of the Brazilian Society of Urology 2010; 36(3): 348-54.






Special Issue - Intellectual Developmental Disability Biobanking (IDDB)